Research & Development Solution Center

  1. The R&D Tax Credit — A Catalyst For Life Sciences Innovation
    2/25/2015

    Does your company develop new medical products, pharmaceuticals, or innovative production techniques in the United States?

  2. Grünenthal Builds A New Entrepreneurial & Networked Approach To R&D
    2/25/2015

    The German proverb, “Wer rastet, der rostet,” loosely translates to, “He who rests grows rusty.” This saying occurs to me as I sit across from Grünenthal’s chief scientific officer, Klaus Langner, Ph.D. We are at the Omni hotel in San Francisco, and it is very late. However, since we are in town for the 33rd Annual J.P. Morgan (JPM) Healthcare conference, each of us knows this is far from our last meeting of the day.

  3. Janssen Pharmaceuticals R&D Adopts A Venture Capital Innovation Model
    12/24/2014

    Faced with diminishing returns on R&D investments, large pharmaceutical companies are searching for innovative ways to successfully identify, develop, and market products with financial viability. Yet small discovery companies and biotechs continue to outpace large pharma in the approval of NMEs (new molecular entities).

  4. From Publish-Or-Perish To Product Creation – Putting Your Research Into Action
    12/24/2014

    Neoantigenics is a biotechnology company that was based on unique IP that was discovered at the University of Virginia (UVA). John Herr, Ph.D., chief scientific officer, is the principal investigator and a tenured professor in the Departments of Cell Biology and Biomedical Engineering at UVA.

  5. ONO Pharmaceutical Strives For Global Sales
    7/31/2014

    Gyo Sagara, president, representative director and CEO, challenges his company to enter the cancer field and gain big-pharma relevance.

  6. An Update On The Buzz Around Oncology
    7/1/2014

    The heightened interest in developing cancer treatments, combined with the R&D efforts contributed to the emergence of a class of “smart bombs” first reported as one of their most hopeful developments at the American Society of Clinical Oncology’s annual meeting in June of 2012.

  7. Driving The Innovation Agenda In Life Sciences: The Case Of Ontario, Canada
    4/30/2014

    Continued discovery is the lifeblood of the life sciences sector. As researchers across the globe race to find the next disruptive treatment or technology, government has a critical role to play in creating the conditions for innovation to flourish.

  8. Antibiotic R&D Gains Traction: A Mid-Cap Company Leads The Way
    4/2/2014

    The industry leader in developing antibiotics against “superbugs” and other multidrug-resistant bacteria is not a Big Pharma corporation, but Cubist Pharmaceuticals, headquartered in Lexington, MA.

  9. The Clinical Research Crystal Ball: Looking At The Future
    3/5/2014

    In the life sciences industry, we are always hyper-vigilant about all of the risks involved in product development. Therefore, our “cuttingedge” approaches seem not quite as innovative as other high-tech industries. The time has come for a few key best practices that add efficiency and cost-effectiveness, something the clinical development world desperately needs. In order to confirm my theories, I queried a number of executivelevel professional colleagues in pharmaceutical and biotechnology companies, who shared their views off the record. I analyzed my queries and compiled the results into a cohesive discussion below. To add a note of practicality to each, I’ll suggest considerations for those who want to make it happen in the present and look toward the future.

  10. Nonantibiotics Spur Biotech-Pharma Collaborations
    3/4/2014

    Since the discovery of penicillin in 1929, the birth of the antimicrobial era meant the beginning of a brave new world, where people no longer died from common bacterial infections, and surgery could be approached with confidence.